NEW YORK, May 21, 2008 (PRIME NEWSWIRE) -- SIGA Technologies, Inc. (Nasdaq:SIGA), a company specializing in the development of pharmaceutical agents to fight biowarfare pathogens, today announced that it has completed a screen of a proprietary small-molecule chemical library in support of its Dengue fever antiviral program. The screen of approximately 200,000 compounds led to the identification of a number of pharmacologically active compounds.
